DOSAGE INDEX / SINGLE
PT-141
Research, reported schedules and supply planning.
Review PT-141 and bremelanotide trials, the approved HSDD indication, desire and distress results, male research and important safety limits.
Source: PeptideDosages.com. Independently written summaries of reported protocols, not validated treatment recommendations. Reviewed for transcription on September 21, 2026.
Research Protocol & Dosage
Source-reported examples · not treatment recommendations
- Amount
- 0.5–1.5 mg per day in this source page
- Frequency
- Once daily in the source
- Cycle / observation period
- 8–12 weeks; source also mentions 16 weeks
- Route / research model
- Subcutaneous
This conflicts with the approved Vyleesi as-needed regimen summarized in our evidence entry. Daily use must not be presented as that product’s labeled schedule.
Titration & progression
A dose range is not a titration schedule. No independently verified stepwise escalation has been established for this source-reported regimen.
Compare the product label or clinical-study schedule
Premenopausal women with acquired, generalized hypoactive sexual desire disorder meeting Vyleesi diagnostic criteria.
The Vyleesi label specifies 1.75 mg subcutaneously as needed, at least 45 minutes before anticipated sexual activity. It limits administration to one dose within 24 hours and recommends no more than eight doses per month. Treatment is discontinued after eight weeks if symptoms do not improve.
It is not indicated for men or sexual-performance enhancement. Uncontrolled hypertension or known cardiovascular disease are contraindications. Blood-pressure changes, nausea and potentially persistent pigmentation matter. A PT-141 research vial is not established as equivalent to this product.
Supply & Planning
Compare vial strengths here. A different vial size changes the available material, not the biological dose.
Diluent & formulation
The approved product is supplied as a prepared solution, with no user reconstitution. Its handling instructions do not establish a diluent for a separately supplied research powder.
Vial comparison
No single complete schedule is resolved for this entry. Enter a documented total to compare strengths; the calculator does not select a regimen.
| Vial strength | Vials needed |
|---|---|
| 10 mg | Enter a total |
Enter a positive material total.
Material minimum only: round total material ÷ vial content up to a whole vial. Actual supply may be higher because of single-use packaging, discard dates, dead space or losses. No validated multi-use storage period is assumed.
Reported Research Results
Selected observations from the cited research. Each finding retains its study population, formulation and limitations.
- A 12-week randomized study reported efficacy data for 327 premenopausal women with female sexual dysfunctions. Pooled higher bremelanotide arms showed a mean increase of 0.7 satisfying sexual events per month, versus 0.2 with placebo. Questionnaire measures of sexual function and distress also improved; nausea, flushing and headache were reported. [1]
- Two randomized, double-blind phase 3 trials assigned 1,267 premenopausal women with HSDD to bremelanotide or placebo for 24 weeks. The safety population included 1,247 women and the primary efficacy population 1,202. The coprimary outcomes were the Female Sexual Function Index desire domain (FSFI-D) and item 13 of the Female Sexual Distress Scale-Desire/Arousal/Orgasm (FSDS-DAO). Integrated differences versus placebo were +0.35 on the desire measure and -0.33 on the distress measure. [2]
- In the primary publication, a patient-perceived-benefit analysis reported responder rates around 58% with bremelanotide versus 35% to 36% with placebo in the two trials. [2]
- Label warnings include transient blood-pressure increases, focal hyperpigmentation and possible effects on oral-drug absorption. Use is contraindicated with uncontrolled hypertension or known cardiovascular disease. The label advises avoiding oral naltrexone used for alcohol or opioid addiction and discontinuing Vyleesi if pregnancy is suspected. [3]
Sourcing & Vendor Information
No compound-specific affiliate destination is listed here yet. Browse the Vendors Index for the available supplier records and disclosed relationships.
Sources & Further Reading
Medical publications and supporting literature from the corresponding protocol bibliographies, combined across vial strengths. Supplier and commercial catalog references are excluded. Duplicate destinations appear once. Inclusion does not mean that a paper validates the reported dose, or that an ingredient study tests the finished blend.
Bibliography checked September 22, 2026: 17 entries mapped from 1 source page. Medical and supporting references are retained below; supplier entries are excluded.
- Original dose-finding trial
- Original RECONNECT publication
- Prescribing safety information
- ScienceDirectFurther reading · Listed in reference bibliography.
- FDANo destination link supplied in the source bibliography.Further reading · Listed in reference bibliography.
- PMC (2022)Further reading · Listed in reference bibliography.
- ResearchGate (2022)Further reading · Listed in reference bibliography.
- Mayo ClinicGeneral guidance · Listed in reference bibliography.
- MedlinePlusGeneral guidance · Listed in reference bibliography.
- CDCGeneral guidance · Listed in reference bibliography.
- CDCGeneral guidance · Listed in reference bibliography.
- CDCGeneral guidance · Listed in reference bibliography.
- PMC (2019)Further reading · Listed in reference bibliography.
- NCBI BookshelfFurther reading · Listed in reference bibliography.
- Diamond LE et al., J Sex Med (2006)Further reading · Listed in reference bibliography.
- Diamond LE et al., J Sex Med (2006)Further reading · Listed in reference bibliography.
- Molinoff PB et al., Ann N Y Acad Sci (2003)Further reading · Listed in reference bibliography.
- Kingsberg SA et al., Obstet Gynecol (2019)Further reading · Listed in reference bibliography.
- Subcutaneous Drug Injection Review (PMC)Further reading · Listed in reference bibliography.
Product-label / dose evidence
Reported schedule reference: PeptideDosages.com. Research findings are summarized independently from the listed sources.